A phase I study of the safety, tolerability, and pharmacokinetics of contezolid acefosamil after intravenous and oral administration in healthy Chinese subjects.

"Hailin Wang, Hong Yuan and Huahui Yang are full-time employees of Shanghai MicuRx Pharmaceutical Co., Ltd. Other authors declare no competing interests."

"This study was supported by Shanghai MicuRx Pharmaceutical Co., Ltd. This study was supported by Shanghai MicuRx Pharmaceutical Co., Ltd., and was funded by grants from Shanghai Municipal Science and Technology Major Project (no. HS2021SHZX001) and Shanghai Municipal Science and Technology Commission Biomedical Technology Support Project (no. 2S11904102)."

"ETHICS APPROVAL: The study protocol and informed consent form of this study have been approved by the institutional review board of Huashan Hospital, Fudan University, and registered with the Clinical Trial Platform of the Center for Drug Evaluation, National Medical Products Administration of China (registration no.: CTR20190111). The study was conducted in strict accordance with the principles of the Declaration of Helsinki and Good Clinical Practice, and relevant regulatory requirements."